Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia

J. A. Jung1†, B. M. Choi3†, S. H. Cho1, S. M. Choe4, J. L. Ghim5, H. M. Lee2, Y. J. Roh6 and G. J. Noh12 *

1 Department of Clinical Pharmacology and Therapeutics and 2 Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap 2-dong, Songpa-gu, Seoul 138-736, Korea. 3 Department of Anesthesiology and Pain Medicine, National Medical Center, 243 Eulji-ro, Jung-gu, Seoul 100-799, Republic of Korea. 4 Division of Clinical Pharmacology, Clinical Research Center, Pusan National University Yangsan Hospital, Gyeongsangnam-Do, Republic of Korea. 5 Clinical Trial Center Yeungnam University Medical Center, Daegu, Republic of Korea. 6 Department of Anesthesiology and Pain Medicine, Seoul National University Boramae Medical Center, 39 Boramae-Gil, Dongjak-Gu, Seoul 156-707, Republic of Korea

*Corresponding author. E-mail: nohgi@amc.seoul.kr

Background. The aims of this study were to investigate the effectiveness, safety, pharmacokinetics, and pharmacodynamics of microemulsion propofol, Aquafol™ (Daewon Pharmaceutical Co., Ltd, Seoul, Republic of Korea).

Methods. In total, 288 patients were randomized to receive 1% Aquafol™ or 1% Diprivan® (AstraZeneca, London, UK) (n=144, respectively). A 30 mg test dose of propofol was administered i.v. over 2 s for assessing injection pain. Subsequently, a bolus of propofol 2 mg kg⁻¹ (−30 mg) was administered. Anaesthesia was maintained with a variable rate infusion of propofol and a target-controlled infusion of remifentanil. Mean infusion rates of both formulations and times to loss of consciousness (LOC) and recovery of consciousness (ROC) were recorded. Adverse events and pharmacokinetic and pharmacodynamic characteristics were evaluated.

Results. Mean infusion rate of Aquafol™ was not statistically different from that of Diprivan® (median: 6.2 vs 6.3 mg kg⁻¹ h⁻¹). Times to LOC and ROC were slightly prolonged in Aquafol™ (median: 21 vs 18 s, 12.3 vs 10.8 min). Aquafol™ showed similar incidence of adverse events to Diprivan®. Aquafol™ (vs Diprivan®) caused more severe (median VAS: 72.0 vs 11.5 mm) and frequent (81.9 vs 29.2%) injection pain. The dose-normalized AUClast of Aquafol™ and Diprivan® was 0.71 (0.19) and 0.74 (0.20) min litre⁻¹. The V₁ of both formulations were proportional to lean body mass. Sex was a significant covariate for k₁₂ and Ce₅₀ of Aquafol™, and for k₄₀ of Diprivan®.

Conclusions. Aquafol™ was as effective and safe as Diprivan®, but caused more severe and frequent injection pain. Aquafol™ demonstrated similar pharmacokinetics to Diprivan®.

Br J Anaesth 2010; 104: 563–76

Keywords: anaesthetics i.v., propofol; model, pharmacodynamic; pharmacokinetics, propofol; safety, drug

Accepted for publication: December 16, 2009

Aquafol™ (Daewon Pharmaceutical Co., Ltd, Seoul, Republic of Korea) is a microemulsion of propofol that has been developed for eliminating lipid solvent-related adverse events of long-chain triglyceride emulsion (LCT) propofol (Diprivan®; AstraZeneca, London, UK), such as infection, fat embolism, hypertriglyceridaemia, and pancreatitis.1 Originally, it was formulated with 8%

†These two authors contributed equally to this work.

‡This article is accompanied by Editorial I.
polyethylene glycol 660 hydroxystearate and 5% tetrahydrofurfuryl alcohol polyethylene glycol ether. A phase 1 study to assess the safety and tolerability of polymeric vehicles of this formulation in healthy volunteers showed dose-limiting toxicities, such as skin rash (Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 2), pain, tenderness and redness at injection sites, urticaria, fever and dizziness, increases of total bilirubin and lactate dehydrogenase, vomiting, chest discomfort, or pain (CTCAE v3.0 grade 1 for all). Subsequently, AquafolTM was reformulated with 10% purified poloxamer 188 (PP188) and 0.7% polyethylene glycol 660 hydroxystearate.

PP188 has been used to treat sickle-cell disease patients with acute chest syndrome because it improves microvascular blood flow by reducing blood viscosity and by reducing friction between red blood cells and vessel walls. PP188 has been studied in more than 4000 patients, and its tolerability and safety have been described in normal subjects, acute myocardial infarction patients, and sickle cell patients.

Alterations in propofol formulation may result in altered pharmacokinetic, pharmacodynamic, and safety characteristics, although our previous microemulsion formulation and LCT propofol were similar in terms of these characteristics within the dose range in an earlier study.

The aims of this study were to investigate the effectiveness (mean infusion rate of propofol during maintenance of anaesthesia), induction [time to LOC and bispectral index (BIS) value at LOC] and recovery characteristics [times to ROC and orientation, and BIS values at ROC and orientation], and safety (incidence and severity of adverse events) of microemulsion propofol in patients undergoing elective surgery under total i.v. anaesthesia. In addition, pharmacokinetic and pharmacodynamic characteristics were evaluated by population analysis using nonlinear mixed-effects modelling.

### Methods

#### Study design

The study was designed as a single-centre, double-blind, randomized, active-controlled, parallel arm, phase 3 clinical trial. The sample size was calculated to detect the equivalence of mean infusion rate during maintenance of anaesthesia between the two propofol formulations. Mean infusion rate was calculated as follows [equation (1)]:

\[
\text{Mean infusion rate of propofol (mg kg}^{-1}\text{h}^{-1}) = \frac{\text{total dose of each propofol formulation}}{\text{body weight} \times \text{maintenance time}}
\]  

In an earlier study comparing the efficacy of generic propofol with Diprivan®, mean infusion rates of both formulations during induction and maintenance of anaesthesia were 5.4 (1.8) and 5.4 (1.2) mg kg\(^{-1}\) h\(^{-1}\), respectively. On the basis of this observation, a sample size of 138 patients per treatment arm was calculated to be sufficient to allow a detection of 15% difference in mean infusion rate with an 80% power at an \(\alpha\) of 0.05.

#### Investigational drugs

The LCT propofol used was 1% Diprivan®, the microemulsion propofol formulation was AquafolTM, which was composed of 1% propofol, 10% PP188, and 0.7% polyethylene glycol 660 hydroxystearate.

#### Patient population

The study was approved by the Institutional Review Board of the Asan Medical Centre (Seoul, Republic of Korea) and written informed consent was obtained from all patients. A total of 288 ASA PS I or II patients who were undergoing stomach, breast, or colorectal surgery were randomly allocated to receive microemulsion (n=144, microemulsion group) or LCT propofol (n=144, LCT group). Of these patients, those consented to arterial blood sampling for pharmacokinetic analysis were 88 (microemulsion group) and 84 (LCT group). The dropout rate was assumed to be 5%. Patients were excluded from the study if they had known allergy to LCT propofol, had abnormal laboratory findings with clinical significance, prior habitual use of psychoactive drugs, or evidence of pregnancy.

#### Study endpoints

The primary endpoint of this study was mean infusion rate (mg kg\(^{-1}\) h\(^{-1}\)) of each propofol formulation during maintenance of anaesthesia. The secondary endpoints were time to LOC, times to ROC and orientation, and BIS values at LOC, ROC, and recovery of orientation. Time to LOC was determined every 5 s after an i.v. bolus of propofol 2 mg kg\(^{-1}\) by the loss of response to verbal command (open your eyes). Time to ROC was assessed every 10 s after the administration of each propofol formulation was discontinued by eye opening to a verbal command. Time to recovery of orientation was assessed every 10 s by appropriate responses to time, place, and person after extubation. Finally, pain on injection, postoperative nausea and vomiting (PONV), postoperative pain, pharmacokinetic and pharmacodynamic characteristics, and safety profiles were evaluated for each formulation.

#### Study procedure

All patients fasted from midnight. Midazolam 7.5 mg was administered orally with sips of water 1 h before surgery. Once in the operating theatre, patients were monitored with electrocardiography, pulse oximetry, end-tidal carbon dioxide partial pressure, invasive arterial pressure (Datex-Ohmeda S/5, Planar Systems, Inc., Beaverton, OR, USA) and BIS (Aspect 2000, Aspect Medical Systems,
Inc., Newton, MA, USA). Using RS232C cables, these data were continuously downloaded to personal computers until recovery from anaesthesia. Each patient was preoxygenated with 100% oxygen via a facemask. To ensure that the trial was double-blind, an independent research nurse prepared the investigational drugs. Each formulation was loaded into 5 and 10 ml syringes for the assessment of pain on injection and induction, respectively, and into 50 ml syringes for the maintenance of anaesthesia. All syringes and tubings were wrapped in opaque and black vinyl. A 20 G catheter was placed into a large vein at the wrist and a second angiocatheter was placed in the contralateral radial artery for frequent blood sampling. A 30 mg test dose of propofol in a microemulsion or LCT formulation was administered i.v. over 2 s to assess pain on injection. Propofol-induced pain of moderate to severe intensity was assessed using a visual analogue scale (VAS >30 mm).11 Subsequently, an i.v. bolus of propofol 2 mg kg$^{-1}$ (~30 mg) was administered. If the patient did not lose consciousness within 1 min, 0.5 mg kg$^{-1}$ of each propofol formulation was additionally administered i.v. When patients were unconscious, propofol was manually infused at variable rates, and remifentanil was administered by a target effect-site concentration-controlled infusion (Asan Pump, version 1.3, Bionet Co., Ltd, Seoul, Republic of Korea).12 Tracheal intubation was facilitated by administering rocuronium 0.6 mg kg$^{-1}$. The lungs of the patients were then ventilated with oxygen in air (1:2), and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 45 mm Hg. The infusion rates of propofol were adjusted by an independent anaesthesiologist to maintain BIS values <60. Target effect-site concentrations of remifentanil were titrated to prevent signs of inadequate anaesthesia13 (stepwise increase by 2 ng ml$^{-1}$) and to maintain stable haemodynamics [systolic arterial pressure (SAP) >80 mm Hg and heart rate (HR) >45 beats min$^{-1}$, stepwise decrease by 2 ng ml$^{-1}$]. If necessary, ephedrine or atropine was administered to maintain SAP above 80 mm Hg and HR above 45 beats min$^{-1}$ during anaesthesia. Neurorwillar block was antagonized by the administration of pyridostigmine and glycopyrrolate at the end of surgery.

**PONV and pain**

Patients who had consented received i.v. patient-controlled analgesia (i.v. PCA). The i.v. PCA device (Accufuser plus$, Wooyoung Medical Co. Ltd, Seoul, Republic of Korea) contained fentanyl 10–15 $\mu$g ml$^{-1}$, ketorolac 1.2–1.8 mg ml$^{-1}$, and ondansetron 80 $\mu$g ml$^{-1}$. The analgesic maintenance dose was set at 10–15 $\mu$g fentanyl (i.e. 1 ml), with a lockout interval of 15 min. The maximum cumulative dose was set at 200–300 $\mu$g fentanyl every 4 h. To prevent PONV, ondansetron 4 mg was injected i.v. at the end of surgery.14 PONV and pain were assessed by an independent research nurse at 6 and 24 h after discontinuation of each propofol formulation. An investigator explained the VAS (0 mm, no pain or nausea; 100 mm, worst pain or nausea imaginable) for propofol-induced pain, postoperative pain, and nausea to patients on the first preoperative day. In this study, positive events of nausea, vomiting, or retching within 6 h and between 6 and 24 h after discontinuation of microemulsion or LCT propofol were designated as early and late PONV, respectively. Patients were instructed to record the frequency of vomiting and retching. An investigator recorded VAS scores for nausea and the frequency of emetic episodes (vomiting and retching). The incidence rates of PONV were assessed by VAS for nausea (>0) or incidence of emetic episodes (>0). Postoperative pain was assessed using a VAS. The need for rescue anti-emetic and analgesic agents was also recorded.

**Safety**

Safety profiles of microemulsion and LCT propofol were evaluated based on incidence rates of adverse events, vital signs, and clinical laboratory test results. Clinical laboratory tests were performed in the screening period, pre-induction period, during anaesthesia, and 24 h after discontinuation of investigational drugs. Hepatorenal function [urinalysis and alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), direct bilirubin, blood urea nitrogen, and creatinine levels], lipid parameters (triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein levels), and coagulation parameters (prothrombin time, activated partial thromboplastin time, and platelet count) were assessed.

**Blood sample acquisition and assay**

Arterial blood samples (4 ml) were obtained at preset intervals: immediately before the administration of investigational drugs, at LOC, and 10, 30, and 60 min after the start of propofol formulation infusion. Samples were also obtained at 0, 1, 6, 12, and 24 h after each propofol formulation was discontinued. Samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes, centrifuged for 10 min at 3500 rpm and then stored at $-70^\circ$C until assay. Plasma concentrations of propofol were measured as described in our earlier study.3 The lower limit of quantification of propofol was 10 ng ml$^{-1}$. The calibration curve was linear over the range of 10–10 000 ng ml$^{-1}$ with the coefficients of determination ($R^2$) >0.999 for all cases. Intra-assay precision values were 0.2–11.0%. Inter-assay within-day and between-day precision values were <14.7% and 6.9%, respectively. Intra-assay accuracy values were 94.1–99.9% of the nominal value. Inter-assay accuracy values were 95.0–103.7% of the nominal value.

**Selection of BIS**

BIS data for pharmacodynamic modelling were selected based on the following criteria, which were similar to
the work of Minto and colleagues\textsuperscript{12} and Kang and colleagues\textsuperscript{15} (i) a baseline BIS value; (ii) a BIS value between the administration of a 30 mg test dose and an i.v. bolus of propofol 2 mg kg\textsuperscript{-1} (\textminus 30 mg); (iii) every 10 s until LOC; (iv) every 30 s until the beginning of propofol infusion; (v) every 1 min during the first 5 min after dosing modulation, and every 5 min between dosing modulations; (vi) every 1 min after the termination of propofol infusion; (vii) at the time points of LOC, ROC, and recovery of orientation.

Pharmacokinetics and pharmacodynamics
The dose-normalized AUC\textsubscript{last} and AUC\textsubscript{inf} (area under the curve from administration to the last measured concentration and to infinity, respectively) were calculated using WinNonlin Professional 5.2 (Pharsight Corporation, Mountain View, CA, USA). The AUC\textsubscript{last} and AUC\textsubscript{inf} were calculated as described in our earlier study.\textsuperscript{3}

One-, two-, and three-compartment models with linear pharmacokinetics were fitted using ADVAN 1, 3, and 11 subroutines and the first-order conditional estimation (FOCE) with interaction procedure of NONMEM\textsuperscript{6} VI level 2 (ICON Development Solutions, Dublin, Ireland). Dissociation between the concentration of propofol and Effect (BIS) was linked with effect compartment.\textsuperscript{5} The relationship between the effect-site concentration of propofol and BIS was analysed using a sigmoid $E_{\text{max}}$ model:\textsuperscript{2}

$$\text{Effect} = E_0 + \left( E_{\text{max}} - E_0 \right) \frac{C_e\gamma}{C_{e50} + C_e\gamma},$$

where Effect is the BIS value, $E_0$ the baseline BIS when no drug is present, $E_{\text{max}}$ the maximum possible drug effect, $C_e$ the calculated effect-site concentration of propofol, $C_{e50}$ the effect-site concentration associated with 50\% maximal drug effect, and $\gamma$ the steepness of the concentration vs response relation. A sigmoid $E_{\text{max}}$ model was fitted using ADVAN 6 subroutine and the FOCE with interaction procedure of NONMEM\textsuperscript{6} VI level 2.

Inter-individual random variability of pharmacokinetic and pharmacodynamic models was modelled using a log-normal or additive model as appropriate. A diagonal matrix was estimated for the different distributions of $\eta$, where $\eta$ is inter-individual random variability with mean zero and variance $\omega^2$. A proportional model was used for the residual random variability. The covariates analysed were age, sex, weight, height, body surface area,\textsuperscript{16} lean body mass (LBM),\textsuperscript{17} effect-site concentration of remifentanil, and SAP.

A 90\% CI was calculated for the ratio of arithmetic mean of each individually predicted pharmacokinetic parameter (half-life, volume of distribution, clearance, volume of distribution at steady state) between microemulsion and LCT propofol, based on an analysis of variance with a linear mixed-effects model that contained an effect for formulation only.

Model diagnostics and validation
Pharmacokinetic and pharmacodynamic models were evaluated using statistical and graphical methods. The minimal value of the objective function (equal to minus twice the log-likelihood) calculated by NONMEM\textsuperscript{6} was used as the goodness-of-fit characteristic to discriminate between hierarchical models using the log-likelihood ratio test.\textsuperscript{18} A P-value of 0.05, representing a decrease in objective function value of 3.84 points, was considered statistically significant ($\chi^2$ distribution, degrees of freedom=1). R (version 2.8.0; R Foundation for Statistical Computing, Vienna, Austria) was used for graphical model diagnostics.

The conditional weighted residuals (CWRES) of pharmacokinetic and pharmacodynamic models were calculated to reduce model misspecification that may result from utilizing weighted residuals with the FOCE method.\textsuperscript{19} Predictive checks were performed by simulating 2000 iterations and comparing simulated prediction intervals with the original data.\textsuperscript{20} A non-parametric bootstrap analysis was performed as an internal model validation (Wings for NONMEM, Nick Holford, Version 614, July 2007, Auckland, New Zealand). Briefly, 2000 bootstrap replicates were generated by random sampling from the original data set with replacement. The final model parameter estimates were compared with the median parameter values and the 2.5\textendash 97.5 percentiles of the non-parametric bootstrap replicates of the final model.

Statistics
Statistical analysis was conducted using R (version 2.8.0, R Foundation for Statistical Computing, Vienna, Austria) or SigmaStat 3.5 for Windows (Systat Software, Inc., Chicago, IL, USA). Data are expressed as mean (SD) for normally distributed continuous variables, median (range) for non-normally distributed continuous variables, and counts and percentages for categorical variables. A P-value of $<0.05$ was considered statistically significant.

Results
Patient population
Enrolment, group assignment, and analysis are shown in Figure 1. Patient characteristics for the safety analysis are summarized in Table 1.

Effectiveness
A variety of variables to compare the effectiveness between the two formulations are shown in Table 2. An additional dose of propofol 0.5 mg kg\textsuperscript{-1} was required to induce LOC in two patients in the microemulsion group and one patient in the LCT group. Time to LOC was
longer than 100 s in these patients. The remainder of the participants lost consciousness after the administration of an i.v. bolus of propofol 2 mg kg$^{-1}$ (30 mg). The bolus dose of propofol did not show significant difference between the two formulations: 122.4 (22.4) mg for microemulsion propofol vs 119.7 (21.9) mg for LCT propofol ($P=0.297$). Times to LOC and ROC of microemulsion propofol were significantly prolonged, but within clinically acceptable ranges. In particular, there were statistically significant differences between sexes in times to LOC, ROC, and time to recovery of orientation (Fig. 2).

Propofol-induced pain

The incidence rates of pain on injection were 81.9% and 29.2% with microemulsion and LCT propofol, respectively ($P<0.001$). These values were estimated from the percentage of all patients in each group who experienced pain on injection (VAS >30 mm). The distribution of VAS scores for propofol-induced pain is shown in Figure 3.

PONV and pain

A total of 122 patients in each group received i.v. postoperative patient-controlled analgesia. The doses of fentanyl, ondansetron, and ketorolac did not show significant differences between the two formulations ($P>0.05$ for all, Mann–Whitney rank-sum test). The incidence rates of
early and late PONV were 9.7% and 8.4% for the microemulsion group and 14.7% and 16.2% for the LCT group, respectively. There were no significant differences in the severity of PONV and postoperative pain between the two formulations (Table 3).

Safety

Overall, a total of 840 adverse events were reported in 288 patients during the study period. A total of 116 patients (80.6%) in the microemulsion group experienced 383 adverse events, and 132 patients (91.7%) in the LCT group experienced 457 adverse events ($P<0.05$, $\chi^2$ test). The numbers of mild, moderate, and severe adverse events were 177, 155, and 51, respectively, in the microemulsion group, and 214, 150, and 93, respectively, in the LCT group ($P<0.05$, $\chi^2$ test). There were no significant differences in measured levels of cholesterol, high-density lipoprotein, and low-density lipoprotein between the two formulations, but serum triglyceride levels in the LCT group were significantly increased during anaesthesia [163 (47, 991) vs 82 (30, 189) mg dl$^{-1}$, respectively, $P<0.05$, Mann–Whitney rank-sum test]. No patient with increased triglyceride levels in the LCT group showed clinical symptoms or signs of pancreatitis.

In nine patients, increased AST and ALT levels spontaneously returned to normal levels within 10 days. Seven patients underwent total gastrectomy (one in each group), distal gastrectomy with gastroduodenectomy (two in the microemulsion group and one in the LCT group), and low anterior resection and abdominoperitoneal resection of the rectum (two in the microemulsion group). Two patients in the LCT group underwent partial hepatectomy and lateral segmentectomy of the liver.

Adverse events of the cardiovascular and hepatorenal systems and lipid and coagulation parameters with causal relation to microemulsion or LCT propofol are shown in Table 4. Ephedrine was administered 39 times in 22 patients of the microemulsion group and 50 times in 27 patients of the LCT group. One patient of the LCT group received one dose of phenylephrine. Atropine was administered 14 times in 10 patients of the microemulsion group and 29 times in 21 patients of the LCT group. Antihypertensive agents (labetalol or nicardipine) were administered 102 times in 56 patients of the microemulsion group and 62 times in 36 patients of the LCT group. Esmolol was administered 14 times to five patients of the microemulsion group and five times to five patients of the LCT group. There were no significant differences in the number of patients who received these drugs between the two groups ($\chi^2$ test).

Other adverse events that were less common (<1%), or considered unrelated to investigational drugs included hypomagnesaemia, hypoprothrombinaemia, haemorrhagic shock, postoperative bleeding, abdominal distension, haematochezia, thrombocytopenia, headache, myodesopsia, delirium, dysphoeea, s.c. emphysema, hyperglycaemia, fever, and low back pain.

One serious adverse event occurred in each of the two groups: postoperative bleeding due to failure of mesenteric artery ligation in the microemulsion group and massive intraoperative bleeding due to rupture of the superior mesenteric vein in the LCT group.

Pharmacokinetics and pharmacodynamics

A total of 863 plasma concentration measurements from 88 patients (71 males and 17 females) receiving...
microemulsion propofol and 834 measurements from 84 patients (67 males and 17 females) receiving LCT propofol were used to determine the pharmacokinetics. Plasma propofol concentration at LOC for one patient receiving microemulsion propofol was 0.02 μg ml\(^{-1}\); this was considered a measurement error and excluded from the non-compartmental and population pharmacokinetic analyses. Body weight, height, and age were 64.8 (9.9) kg, 166.5 (148.0–182.0) cm, and 57.5 (28.0–71.0) yr, respectively, for patients receiving microemulsion formulation, and 64.3 (8.6) kg, 167.0 (150.0–182.0) cm, and 54 (25.0–72.0) yr, respectively, for patients receiving LCT formulation. There were no significant differences in any of these characteristics, including sex, between the two formulations (two sample t-test, Mann–Whitney rank-sum test or \(\chi^2\) test as appropriate). A total of 7448 BIS values from 87 patients receiving microemulsion propofol and 6777 BIS values from 83 patients receiving LCT propofol were used to determine the pharmacodynamics.

The cumulative propofol dose of microemulsion propofol at each sampling point was not significantly different from that of LCT propofol (Fig. 4A). At LOC, there were no significant differences in the plasma concentrations of microemulsion (13.3, 0.02–32.0 μg ml\(^{-1}\)) and LCT propofol (11.9, 2.3–38.0 μg ml\(^{-1}\)) (Mann–Whitney rank-sum test) (Fig. 4B). Plasma propofol concentrations during infusion (except at LOC) and up to 1 h after discontinuation of propofol infusion were consistently lower in patients receiving microemulsion propofol (Fig. 4C). The dose-normalized AUC\(_{\text{last}}\) and AUC\(_{\text{inf}}\) were 0.71 (0.19)
and 0.74 (0.20) min litre⁻¹ for microemulsion propofol and 0.74 (0.20) and 0.77 (0.20) min litre⁻¹ for LCT propofol, respectively. Ninety per cent confidence intervals calculated for the ratio of geometric means of dose-normalized AUCl₅₅ and AUCl₉₉ were 89.3–108.4 and 89.6–108.9, respectively.

The final pharmacokinetic model of microemulsion propofol included LBM and sex as a significant covariate for Vₐ and kₐ, respectively, whereas that of LCT propofol, LBM for V₁. The final pharmacokinetic models resulted in an improvement in the objective function values (31.58, P<0.0001 for microemulsion propofol; 18.24, P<0.01 for LCT propofol) compared with the basic models. Sex was a significant covariate for Ce₅₀ and kₙ₀ in the final model of microemulsion propofol and LCT propofol, respectively. The final pharmacodynamic models resulted in an improvement in the objective function values (15.297, P<0.001 for microemulsion propofol; 13.206, P<0.001 for LCT propofol).
propofol) compared with the basic models. The CWRES vs predicted propofol concentrations or BIS values, and predictive checks of the final models are shown in Figure 5 (pharmacokinetics) and Figure 6 (pharmacodynamics), respectively. Population parameter estimates and median parameter values (2.5\%-97.5\%) of the non-parametric bootstrap replicates of the final pharmacokinetic and pharmacodynamic models for microemulsion and LCT propofol are summarized in Tables 5 and 6, respectively. Table 7 shows the 90\% CI of the ratio of arithmetic mean of each individually predicted pharmacokinetic parameters between microemulsion and LCT propofol.
Microemulsion propofol was as effective and safe as LCT propofol, and demonstrated similar pharmacokinetic characteristics to LCT propofol in terms of dose-normalized AUCs. As expected, microemulsion propofol did not increase serum triglyceride levels during administration, but caused more severe and more frequent pain on injection. The increased frequency and severity of pain on injection seen with current microemulsion formulation may be associated with a high aqueous-free propofol concentration: 63.3 (1.2) vs 12.4 (0.7) μg ml⁻¹ in LCT propofol.³ However, lipid solvent-induced hypertriglyceridaemia and pancreatitis can be avoided with microemulsion propofol. Moreover, we observed good stability at stress condition [temperature=60 (SD 2) °C] for 4 weeks and good compatibility with various drugs and fluids used during anaesthesia (data not shown, July 28, 2008, Tae-Won Song, MS, Central Research Laboratories, Daewon Pharmaceutical Co.). As a result, microemulsion propofol may reduce the occurrence of fat embolism caused by phase separation of LCT formulation.²²

The safety evaluation of PP188 has focused on its effects on the kidney, liver, and platelets. Renal function was not influenced by PP188.⁵ Hepatic function tests showed modestly but transiently increased levels of markers, particularly direct bilirubin and ALT levels.⁵ ⁸ Transient and mild thrombocytopenia was also observed, but there were no dose- or time-related significant decreases in platelet count.⁸ In this study, we did not observe any abnormal laboratory test results of the liver, kidney, and platelet with causal relation to microemulsion propofol. In three patients receiving microemulsion propofol who underwent gastrectomy, the potential causes of increased AST and ALT levels are unknown. An aberrant left hepatic artery, arising from the left gastric artery either as an accessory or replacing the left hepatic artery, is seen in 44% of patients with gastric cancer.²³ Like PP188,⁵ ⁸ resection of this artery as part of the gastrectomy...
procedure may cause transient and reversible liver dysfunction.\textsuperscript{24} Unfortunately, we did not identify aberrant left hepatic arteries in these patients.

PP188 has been reported to cause three cases of non-immunoglobulin E-mediated hypersensitivity reaction, known as C-activation-related pseudoallergy (CARPA),\textsuperscript{25} although perioperative anaphylaxis to LCT propofol has also been reported.\textsuperscript{26} Less than 5% of PP188 is metabolized and renal excretion accounts for more than 90% of its clearance from the human body.\textsuperscript{27} Clinical investigations for CARPA and in patients with renal insufficiency are required to further demonstrate the safety of microemulsion propofol.

Our previous microemulsion formulation showed smaller $V_1$ and less extensive peripheral distribution (smaller $V_3$ and $V_{\text{dss}}$) than those of LCT propofol.\textsuperscript{2} However, current microemulsion propofol showed smaller $V_1$ and more extensive peripheral distribution (larger $V_2$, $V_3$, and $V_{\text{dss}}$) than those of LCT propofol. The opposite findings in peripheral distribution between previous and current microemulsion propofol may be attributed to different polymeric vehicles of propofol. Although pharmacokinetic studies of polyethylene glycol 660 hydroxystearate and tetrahydrofuranyl alcohol polyethylene glycol ether were not found in the literatures, we thought that previous microemulsion formulation was less extensively distributed to peripheral

---

Fig 6 Predictive checks of the final pharmacodynamic models and CWRES vs predicted BIS. (A) Predictive check for microemulsion propofol. (B) CWRES vs predicted BIS for microemulsion propofol. (C) Predictive check for LCT propofol. (D) CWRES vs predicted BIS for LCT propofol. Less than 10% of the data distributed outside the 90% prediction intervals, indicating that the final pharmacodynamic models (3.0% for microemulsion propofol and 2.4% for LCT propofol) for both formulations adequately describe the time-courses of BIS. Empty area between grey horizontal marks (\textminus): 90% prediction intervals.
Basic modelled using log-normal and proportional models, respectively. Non-parametric bootstrap analysis was repeated 2000 times. CV, coefficient of variation; \( \sigma^2 \), variance of residual random variability; RSE, relative standard error; SE estimate \( \times 100 \) (\%). *Lean body mass (kg)

<table>
<thead>
<tr>
<th>Model</th>
<th>Parameter</th>
<th>Microemulsion propofol (n=88)</th>
<th>LCT propofol (n=84)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( V_1 ) (litre)</td>
<td>4.49 (12.9, 25.2)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( k_{10} ) (min(^{-1}))</td>
<td>0.347 (12.9, 9.68)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( k_{12} ) (min(^{-1}))</td>
<td>0.286 (17.8, 28.1)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( k_{21} ) (min(^{-1}))</td>
<td>0.0131 (5.32, ---)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( k_{13} ) (min(^{-1}))</td>
<td>0.105 (13.7, ---)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( k_{23} ) (min(^{-1}))</td>
<td>0.00009 (6.27, ---)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( \sigma^2 )</td>
<td>0.0871 (12.06, ---)</td>
<td>---</td>
</tr>
<tr>
<td>Final</td>
<td>( V_1 ) (litre)</td>
<td>0.088 (12.1)(^<em>)LBM(^</em>) (21.2)</td>
<td>0.088 0.063–0.113</td>
</tr>
<tr>
<td></td>
<td>( k_{10} ) (min(^{-1}))</td>
<td>0.355 (13.1, 6.36)</td>
<td>0.352 0.272–0.501</td>
</tr>
<tr>
<td></td>
<td>( k_{12} ) (min(^{-1}))</td>
<td>0.312 (17.0, 27.9) for male</td>
<td>0.309 0.217–0.477</td>
</tr>
<tr>
<td></td>
<td>( k_{22} ) (min(^{-1}))</td>
<td>0.222 (18.6, 27.9) for female</td>
<td>0.221 0.149–0.351</td>
</tr>
<tr>
<td></td>
<td>( k_{31} ) (min(^{-1}))</td>
<td>0.0131 (7.38, ---)</td>
<td>0.0131 0.0114–0.0151</td>
</tr>
<tr>
<td></td>
<td>( k_{33} ) (min(^{-1}))</td>
<td>0.108 (12.7, ---)</td>
<td>0.107 0.082–0.152</td>
</tr>
<tr>
<td></td>
<td>( k_{41} ) (min(^{-1}))</td>
<td>0.00896 (9.83, ---)</td>
<td>0.000893 0.000739–0.001050</td>
</tr>
<tr>
<td></td>
<td>( \sigma^2 )</td>
<td>0.0881 (12.03, ---)</td>
<td>0.0870 0.0708–0.1089</td>
</tr>
</tbody>
</table>

Table 6 Population pharmacodynamic parameter estimates, inter-individual variability, and median parameter values (2.5–97.5%) of the non-parametric bootstrap replicates of the final pharmacodynamic model of microemulsion and LCT propofol for the electroencephalographic BIS. *Inter-individual random variability was modelled using additive model. No inter-individual random variability was assumed; inter-individual random variability of other structural model parameters including \( E_{\text{max}} \) of LCT propofol was modelled using a log-normal model. †Residual random variability was modelled using a proportional model. Non-parametric bootstrap analysis was repeated 2000 times. CV, coefficient of variation; \( \sigma^2 \), variance of residual random variability; RSE, relative standard error; SE estimate \( \times 100 \) (\%).

<table>
<thead>
<tr>
<th>Model</th>
<th>Parameter</th>
<th>Microemulsion propofol (n=87)</th>
<th>LCT propofol (n=83)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td>( E_0^* )</td>
<td>85.4 (1.02, ---)</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>( E_{\text{max}}^* )</td>
<td>30.2 (4.80, ---)</td>
<td>27.2 (5.77, 29.7)</td>
</tr>
<tr>
<td></td>
<td>( C_{E0} ) (\mu g ml(^{-1}))</td>
<td>1.72 (3.05, 26.7)</td>
<td>1.96 (3.68, 29.8)</td>
</tr>
<tr>
<td></td>
<td>( \gamma^1 )</td>
<td>5.56 (8.29, ---)</td>
<td>4.35 (8.09, ---)</td>
</tr>
<tr>
<td></td>
<td>( k_{40} ) (min(^{-1}))</td>
<td>0.0802 (3.70, 33.8)</td>
<td>0.140 (5.58, 48.1)</td>
</tr>
<tr>
<td></td>
<td>( \sigma^{21} )</td>
<td>0.0246 (8.98, 15.7)</td>
<td>0.0226 (0.33, ---)</td>
</tr>
<tr>
<td>Final</td>
<td>( E_0^* )</td>
<td>85.4 (1.02, ---)</td>
<td>85.4 83.6–87.0</td>
</tr>
<tr>
<td></td>
<td>( E_{\text{max}}^* )</td>
<td>30.2 (4.77, ---)</td>
<td>27.5 (5.78, 29.6)</td>
</tr>
<tr>
<td></td>
<td>( C_{E0} ) (\mu g ml(^{-1}))</td>
<td>1.63 (2.97, 24.3) for male</td>
<td>1.95 (3.61, 29.3)</td>
</tr>
<tr>
<td></td>
<td>( \gamma^1 )</td>
<td>2.15 (7.07, 24.3) for female</td>
<td>1.81–2.10</td>
</tr>
<tr>
<td></td>
<td>( k_{40} ) (min(^{-1}))</td>
<td>0.0803 (3.67, 33.6)</td>
<td>0.135 (6.01, 51.8) for male</td>
</tr>
<tr>
<td></td>
<td>( \sigma^{21} )</td>
<td>0.0246 (8.98, 15.7)</td>
<td>0.0226 (0.33, ---)</td>
</tr>
</tbody>
</table>

Table 7 Comparison of population pharmacokinetic parameters between microemulsion and LCT propofol. *On the basis of an analysis of variance with a linear mixed effects model that contained an effect for formulation only.

<table>
<thead>
<tr>
<th>Parameter (unit)</th>
<th>Microemulsion propofol (n=88)</th>
<th>LCT propofol (n=84)</th>
<th>Ratio(^*)</th>
<th>90% confidence interval(^*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( V_1 ) (litre)</td>
<td>4.50 0.99</td>
<td>6.78 1.01</td>
<td>66.32 62.62–70.03</td>
<td></td>
</tr>
<tr>
<td>( V_2 ) (litre)</td>
<td>105.00 33.29</td>
<td>77.25 15.52</td>
<td>135.93 127.38–144.47</td>
<td></td>
</tr>
<tr>
<td>( V_3 ) (litre)</td>
<td>542.83 118.91</td>
<td>398.11 59.15</td>
<td>136.35 130.36–142.35</td>
<td></td>
</tr>
<tr>
<td>( V_{\text{bas}} ) (litre)</td>
<td>652.39 148.007</td>
<td>482.14 74.10</td>
<td>135.31 129.14–141.48</td>
<td></td>
</tr>
<tr>
<td>( C_L ) (litre min(^{-1}))</td>
<td>1.60 0.37</td>
<td>1.46 0.28</td>
<td>109.63 103.94–115.32</td>
<td></td>
</tr>
<tr>
<td>( C_L\text{ (litre min}(^{-1}))</td>
<td>1.38 0.44</td>
<td>1.04 0.21</td>
<td>132.37 124.38–141.17</td>
<td></td>
</tr>
<tr>
<td>( C_L\text{ (litre min}(^{-1}))</td>
<td>0.49 0.11</td>
<td>0.37 0.05</td>
<td>132.37 126.52–138.23</td>
<td></td>
</tr>
<tr>
<td>( t_{1/2}\text{ (min)} )</td>
<td>0.91 0.08</td>
<td>1.63 0.12</td>
<td>55.39 53.85–56.93</td>
<td></td>
</tr>
<tr>
<td>( t_{1/2}\text{ (min)} )</td>
<td>86.99 7.55</td>
<td>81.32 4.09</td>
<td>106.98 105.08–108.87</td>
<td></td>
</tr>
<tr>
<td>( t_{1/2}\text{ (min)} )</td>
<td>1021.14 8.63</td>
<td>951.79 21.69</td>
<td>107.29 106.85–107.72</td>
<td></td>
</tr>
</tbody>
</table>
tissues, compared with LCT propofol. On the other hand, PP188 is a highly water-soluble non-ionic polymer with preferential distribution to the extracellular fluid and widely distributed throughout the well-perfused organs and tissues in rats. In this study, the number of the first post-dose blood samples was 87 for microemulsion propofol and 84 for LCT propofol. Of these, plasma propofol concentrations (median, 25–75%) of the samples obtained before 1 min after an i.v. bolus of propofol 2 mg kg\(^{-1}\) were (13.8, 9.2–21.0) \(\mu\)g ml\(^{-1}\) for microemulsion propofol \((n=62)\) and (12.4, 8.5–19.2) \(\mu\)g ml\(^{-1}\) for LCT propofol \((n=68)\). These higher propofol concentrations before 1 min after an i.v. bolus may account for smaller \(V_1\) of microemulsion formulation. After 1 min after an i.v. bolus, the difference in plasma propofol concentrations of the first post-dose samples between the two formulations was decreased, that is, 11.1, 8.9–19.6 \(\mu\)g ml\(^{-1}\) for microemulsion propofol \((n=25)\), 10.9, 5.1–15.8 \(\mu\)g ml\(^{-1}\) for LCT propofol \((n=16)\). On the basis of these findings, we speculated that during the initial period (<1 min after an i.v. bolus), LCT propofol may distribute more extensively in blood due to lipid solvent, compared with previous and current microemulsion formulations, and current microemulsion nanodroplets may begin to extensively distribute to well-perfused peripheral organs and tissues after the initial period, owing to the property of PP188.

Slightly slower onset of sleep in patients receiving microemulsion propofol can be explained by the smaller \(k_{eo}\) value of microemulsion propofol. More prolonged recovery of microemulsion propofol can be explained pharmacokinetically in the whole population (higher \(V_{dss}\)) and pharmacodynamically in male patients receiving microemulsion propofol (lower \(C_{e50}\) than that of patients receiving LCT propofol).

In agreement with results of our previous study, there were differences in clinical endpoints such as times to LOC, ROC, and recovery of orientation between male and female patients. We observed that all of the individually predicted clearances and volumes, including \(V_{dss}\), were significantly greater in males than in females, irrespective of formulations (data not shown). For microemulsion propofol, larger \(V_2\) [114.4 (28.8) \(\times\) 65.9 (19.3) litres for female], with possibly lower rate of increasing of effect-site concentrations of propofol may partly account for the slightly delayed onset of sleep in males. For LCT propofol, larger \(V_2\) [80.9 (14.5) \(\times\) 62.7 (10.2) litres for female] as well as lower \(k_{eo}\) may account for the slightly delayed onset of sleep in males. Prolonged recovery in male patients receiving microemulsion propofol may be attributed to \(V_{dss}\) [683.3 (139.7) \(\times\) 523.2 (108.7) litres for female] as well as smaller \(C_{e50}\) in male patients. For LCT propofol, larger \(V_{dss}\) [502.2 (64.0) \(\times\) 403.2 (57.4) litres for female] may account for prolonged recovery in male patients.

There were several issues to be considered as limitations of this study. First, the initial plasma propofol concentrations after a bolus dose were not measured extensively. This sparse sampling may not be sufficient for describing pharmacokinetics of rapidly acting propofol formulations. However, we believe that population analysis in a relatively large patient population and a relatively wide range of the time points for the first post-dose samples (0.9–3.5 min and 0.9–3.1 min after a bolus of propofol, for microemulsion and LCT propofol, respectively) may, at least in part, counterbalance this issue. Secondly, most pharmacokinetic models used for target-controlled infusion of propofol were derived from infusion data and the initial plasma propofol concentrations after a bolus are significantly underpredicted by the parameters obtained from the infusion data. Therefore, pharmacokinetic and pharmacodynamic study using zero-order infusion of microemulsion propofol should be performed. Thirdly, pharmacodynamic characteristics of both formulations were described without considering the effects of remifentanil on the BIS. However, this might be a minor issue, because the relationship between the effect-site concentration of propofol and BIS was preserved with or without opioids.

In conclusion, AquafolTM is an effective and safe microemulsion formulation of propofol. However, current microemulsion propofol caused more severe and frequent pain on injection compared with LCT propofol, for which aggressive prevention is essential. Population pharmacokinetic and pharmacodynamic modelling well described the differences of effectiveness between the two formulations. Microemulsion propofol should be further evaluated in patients with renal insufficiency and for any increased incidence of CARPA.

Acknowledgements
We are grateful to Ae-Kyung Hwang, BS, Hyun-Jeong Park, BS, and Arum Kim, BS from the Clinical Research Center of Asan Medical Center (Seoul, Republic of Korea) for performing the propofol concentration measurements. We are also deeply grateful to Jung-Sim Yang, AS, Dong-Hy Kim, AS, Yun-Hee Kang, AS, and Chi-Joo Ahn, CNA, from Asan Medical Center for their efforts as clinical research coordinators.

Funding
This work was supported by the Korea Healthcare Technology R&D Project, Ministry of Health Welfare, Korea (Grant number: A070001).

References
1 Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005; 103: 860–76
4. CTEP. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Bethesda Division of Cancer Treatment and Diagnosis (DCPT). National Cancer Institute (NCI), U.S. National Institutes of Health (NIH), 2006